

Lab resource: Stem Cell Line

Generation of a human iPSC line, FINCBI001-A, carrying a homoplasmic m.G3460A mutation in MT-ND1 associated with Leber's Hereditary optic Neuropathy (LHON)

Camille Peron^a, Roberta Mauceri^a, Tommaso Cabassi^a, Alice Segnali^a, Alessandra Maresca^b, Angelo Iannielli^{c,e}, Ambra Rizzo^d, Francesca L. Sciacca^d, Vania Broccoli^{c,e}, Valerio Carelli^{b,f}, Valeria Tiranti^{a,*}

^a Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy

^b IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy

^c Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy

^d Laboratory of Clinical Investigation, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy

^e National Research Council (CNR), Institute of Neuroscience, Milan, Italy

^f Department of Biomedical and Neuromotor Sciences — DIBINEM, University of Bologna, Bologna, Italy

ABSTRACT

Leber's Hereditary Optic Neuropathy (LHON) is a maternally inherited disorder caused by homoplasmic mutations of mitochondrial DNA (mtDNA). LHON is characterized by the selective degeneration of the retinal ganglion cells (RGC). Almost all LHON maternal lineages are homoplasmic mutant (100% mtDNA copies are mutant) for one of three frequent mtDNA mutations now found in over 90% of patients worldwide (m.11778G > A/MT-ND4, m.3460G > A/MT-ND1, m.14484 T > C/MT-ND6). Human induced pluripotent stem cells (hiPSCs) were generated from a patient carrying the homoplasmic m.3460G > A/MT-ND1 mutation using the Sendai virus non-integrating virus.

1. Resource table

Unique stem cell line identifier	FINCBI001-A
Alternative name(s) of stem cell line	F56L cl33
Institution	Fondazione IRCCS Istituto Neurologico C. Besta
Contact information of distributor	Valeria Tiranti, valeria.tiranti@istituto-besta.it
Type of cell line	iPSC
Origin	Human
Additional origin info	Age: 21 Sex: Female Ethnicity if known: Caucasian/Italian
Cell Source	Skin fibroblasts
Clonality	Clonal
Method of reprogramming	Sendai Virus
Genetic Modification	NO
Type of Modification	N/A
Associated disease	LHON
Gene/locus	m.3460G > A/MT-ND1
Method of modification	N/A

Name of transgene or resistance	N/A
Inducible/constitutive system	N/A
Date archived/stock date	13/05/2019
Cell line repository/bank	N/A
Ethical approval	Fondazione IRCCS Istituto Neurologico Carlo Besta, approval number 43-2013, date 26/6/2013

2. Resource utility

LHON disease is a mitochondrial disorder affecting RGC. The generation of iPSC from affected patients gives the unique opportunity to generate in vitro retinal neuronal cells, which are not accessible in vivo.

3. Resource details

LHON is characterized by the selective degeneration of retinal ganglion cells (RGCs), the terminal retinal neurons projecting to the brain their optic nerve-forming axons, which leads to permanent blindness (Carelli et al., 2017; Man, 2002). Despite the causative mutations are present in all tissues, yet only a specific cell type is affected.

* Corresponding author.

E-mail address: valeria.tiranti@istituto-besta.it (V. Tiranti).

<https://doi.org/10.1016/j.scr.2020.101939>

Received 8 July 2020; Received in revised form 23 July 2020; Accepted 28 July 2020

Available online 03 August 2020

1873-5061/ © 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Fig. 1.

Our deep understanding of the pathogenic mechanism is thus hampered by the lack of appropriate models, still preventing the development of effective therapies.

Skin fibroblasts from a 21 year old female patient carrying the m.3460G > A in the mitochondrial gene MT-ND1 (Fig. 1A) were used to generate iPSC colonies by the non-integrating Sendai Virus System-mediated (CytoTune™-iPS 2.0 Sendai Reprogramming Kit from Life Technologies) introduction of the four key factors of Yamanaka (*OCT3/4*, *SOX2*, *c-MYC* and *KLF4*) (Takahashi et al., 2007). Colonies were controlled for typical stem cell morphology (Fig. 1B) and a colorimetric assay designed to measure Alkaline Phosphatase activity was also performed (Fig. 1C). Clones' fully characterization was done investigating the expression of master regulators of pluripotent stem cells and associated markers, assessed by immunofluorescence for Oct4, Nanog and Tra1-60 (Fig. 1D, E) and RT-PCR for *NANOG*, *REX1*, *SOX2* and *OCT4* (Fig. 1F), and specific ability to generate Embryoid Bodies (EBs), composed by cells from all three germ layers (Fig. 1G, H). RT-PCR analysis showed the endogenous expression of the three germ layers markers *MSX1*, *PAX6* and *FOXA2* (Fig. 1I). Karyotype analysis was performed by CGH-array (Table 1). PCR-based detection tests confirmed the absence of Mycoplasma contamination at this stage. In addition, microsatellite PCR profiling confirmed that these iPSC lines had the same genetic identity with respect to the donor's fibroblasts (Data available with the authors).

4. Materials and methods

4.1. Reprogramming in iPSC

Skin fibroblasts were collected to generate iPSC colonies using the CytoTune™-iPS 2.0 Sendai Reprogramming Kit (Life Technologies).

4.2. Cell culture

iPSC were grown on 1:100 Cultrex® Stem cell qualified Reduced Growth factor basement membrane matrix (Trevigen) and fed with the Essential 8™ Flex medium (Gibco). Colonies were passaged every 3 days using 0,5mM EDTA-Na2 solution, adding 10uM Y27632 (DBA) in the new medium. Then medium was changed without Y27632. In order to obtain embryoid bodies (EBs), when iPSC reached 70–80% confluence, little clumps of colonies were cultivated in suspension in Essential 8 medium plus 1X N2 Supplement (Life Technologies), 5 ng/ml Noggin Recombinant Protein (Tebu Bio), 10 μM SB431542 (Sigma) and Y27632 for 4–8 days. Medium without Y27632 was changed every other day. EBs were then plated on 1:100 Cultrex® Stem cell for 4–8 days to obtain rosette-like formations. Pellets of iPSC and EBs were used to perform RNA extraction.

Table 1
Characterization and validation.

Classification	Test	Result	Data
Morphology Phenotype	Photography	Normal	Fig. 1B
	Alkaline phosphatase Staining Immunocytochemistry	Staining resulted positive Staining of pluripotency markers OCT4; Tra-1-60; Nanog	Fig. 1C Fig. 1D, E
Genotype Identity	RT-PCR	Expression of pluripotency markers OCT4, SOX2, REX1, NANOG	Fig. 1F
	CGH array Microsatellite PCR (mPCR)	arr(1-22,X)x2, normal female 6 loci analyzed, all matching	Supplementary file Data available with the Authors
Mutation analysis (IF APPLICABLE)	Sequencing Southern Blot OR WGS	Homoplasmic mtDNA mutation N/A	Fig. 1A
Microbiology and virology Differentiation potential	Mycoplasma Embryoid body formation and characterization by RT-PCR	Mycoplasma testing by MycoAlert was Negative Expression of three germ layers markers PAX6 (ectoderm), MSX1 (mesoderm), FOXA2 (endoderm)	Fig. 1G-I
Donor screening (OPTIONAL) Genotype additional info (OPTIONAL)	HIV 1 + 2 Hepatitis B, Hepatitis C Blood group genotyping HLA tissue typing	N/A N/A N/A	

Table 2
Reagents details.

Antibodies used for immunocytochemistry/flow-citometry			
	Antibody	Dilution	Company Cat # and RRID
Pluripotency Markers	Rabbit anti-NANOG	1:100	ReproCELL Incorporated Cat# RCAB004P-F, RRID:AB_1560380
	Mouse anti-TRA1-60	1:200	Abcam Cat# ab16288, RRID:AB_778563
	Rabbit anti-OCT4	1:200	Abcam Cat# ab19857, RRID:AB_445175
Secondary antibodies	Goat anti-Mouse IgG Alexa Fluor 546	1:1000	Thermo Fisher Scientific Cat# A-11030, RRID:AB_2534089
	Goat anti-Rabbit IgG Alexa Fluor 488	1:1000	Thermo Fisher Scientific Cat# A-11034, RRID:AB_2576217
Primers	Target	Forward/Reverse primer (5'-3')	
Pluripotency Markers	NANOG	CATGGATCTGCTTATTTCAGGAC/GGTTCCAGGATGTTGGAGAGTT	
	REX1	CAGATCCTAAACAGCTCGCAGAAT/GCGTACGCAAATTAAGTCCAGA	
	SOX2	GAATGCCTTCATGGTGTGGTC/GCTTAGCCTCGTCGATGAAC	
	OCT4	ATCCTCGGACCTGGCTAAGC/TCTCCAGCTTCACGGCACCA	
House-Keeping Genes	GAPDH	GTGTGAACCATGAGAAGTATGACAAC/CTTACCACCTTCTTGATGTCATC	
Targeted mutation analysis	m.3460G > A	CGAAAGGACAAGAAAATAA/GAGGTTGACCAGGGGGTTGGGTAT	
Differentiation Markers (ectoderm)	PAX6	ACCCATTATCCAGATGTGTTTCCCGAG/ATGGTGAAGCTGGCATAGGCCGCGAG	
Differentiation Markers (mesoderm)	MSX1	CGAGAGGACCCCGTGGATGCAGAG/GGCGGCCATCTTCAGCTTCTCCAG	
Differentiation Markers (endoderm)	FOXA2	GGAGCGGTGAAGATGGAA/TACGTGTTTCATGCCGTTTCAT	
Short Tandem Repeats Markers	ApoB (Chr 2)	ATGGAACCGGAGAAATTATG/CCTTCTCACTTGGCAAATAC	
	D10S1214 (Chr 10)	ATTGCCCCAAAACITTTTGG/TTGAAGACCAAGTCTGGGAAG	
	D11S533 (Chr 11)	GCCTAGTCCCTGGGTGTGGTC/GGGGGTCTGGGAACATGTCCCC	
	D17S1290 (Chr 17)	GCAACAGAGCAAGACTGTC/GGAAACAGTTAAATGGCCAA	
	D19S894 (Chr 19)	TTACTTGGCCCCAGGAAGC/GTTAAGCCATAAACATGGAATGACC	
	D21S2055 (Chr 21)	AACAGAACCAATAGGCTATCTATC/TACAGTAAATCACTTGGTAGGAGA	

4.3. Immunofluorescence

IPSC were fixed using cold EtOH for 15' at -20°C . Antigen retrieval was performed by incubating fixed colonies in 1 mM EDTA solution for 15' at 65°C . Cells were washed three times with PBS + 1% BSA and then permeabilized in PBS + 0.5% Triton for 10' at room temperature (RT) and washed again. After 1 h of blocking solution (PBS + 10% NGS + 1% BSA) at RT, cells were incubated at 4°C overnight with primary antibodies (Table 2) in PBS + 3% NGS + 1% BSA. Cells were then washed and incubated for 1 h at RT with secondary antibodies (Table 2), washed again and then observed with a Leica TCS SP8 confocal microscope.

4.4. Rt-PCR

RNA extraction was performed with the RNeasy Mini Kit (Quiagen) and retrotranscription with the GoTaq[®]2-Step RT-qPCR System (Promega). RT-PCR was conducted using primers in Table 2.

4.5. Alkaline phosphatase staining

IPSC were fixed with 2% PFA for 10' at RT and washed three times. Cells were then incubated with the Sigmafast[™] BCIP[®]/NBT substrate (Sigma) for 20' at RT and visualized with a phase-contrast microscope.

4.6. CGH

Deletion and duplication of nuclear DNA were verified by array Comparative Genomic Hybridization (CGH). DNA was extracted from cultured iPSC cells (about 1×10^6 cells) using DNA extraction kit (Gentra kit, Qiagen, Hilden, Ge). Array CGH analyses were performed using Cytosure oligo ISCA60K platform: array design was performed by Oxford Gene Technology (OGT, Begbroke, Oxfordshire, UK) and manufactured by Agilent Technologies (Santa Clara, CA, USA). The DNA test was hybridized with sex-matched DNA from pooled controls (reference DNA, Promega, Madison, Wisconsin, USA), according to the manufacturer's protocol. Data were analyzed using Cytosure Interpret software (OGT). Clinical interpretation of array CGH results are based on published literature and public databases (ENSEMBL, USBC,

Database for Genetic Variants, DECIPHER, the Italian database of Troina) following Cytogenetic European and International Guidelines (Hastings et al., 2012; Mascarello et al., 2011). Genomic coordinates are based on the February 2009 Human Genome Build (GRCh37/hg19).

4.7. Sequencing

Sanger sequencing was performed using a 3130 Abi Prism sequencer.

4.8. Mycoplasma

MycoAlert mycoplasma detection Kit (Lonza) was used.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The financial support of Mitocon – Italy, Grant no. 2018-01 to VT

and of the grant from the Italian Ministry of Health RF-2018-12366703 to VC, VB and VT is acknowledged.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.scr.2020.101939>.

References

- Carelli, V., La Morgia, C., Ross-Cisneros, F.N., Sadun, A.A., 2017. Optic neuropathies: the tip of the neurodegeneration iceberg. *Hum. Mol. Genet.* 26, R139–R150.
- Hastings, R., Howell, R., Bricarelli, F.D., Kristofferson, U., Cavani, S., 2012. A common European framework for quality assessment for constitutional, acquired and molecular cytogenetic investigations. *ECA Newsl.* 29, 7–25.
- Man, P.Y.W., 2002. Leber hereditary optic neuropathy. *J. Med. Genet.* 39, 162–169.
- Mascarello, J.T., Hirsch, B., Kearney, H.M., Ketterling, R.P., Olson, S.B., Quigley, D.I., Rao, K.W., Tepperberg, J.H., Tsuchiya, K.D., Wiktor, A.E., 2011. Section E9 of the American college of medical genetics technical standards and guidelines: fluorescence in situ hybridization. *Genet. Med.* 13, 667–675.
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S., 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131, 861–872.